申请人:MONSANTO COMPANY
公开号:EP0494063A2
公开(公告)日:1992-07-08
A method is described for inhibiting IgE production which comprises administering, in an amount effective to inhibit IgE production, a prostaglandin of the formula :
or a pharmaceutically acceptable non-toxic salt thereof, in which R is hydrogen, C1-C5 alkyl, C3-C8 cycloalkyl, phenyl, or mono, di- or tri-substituted phenyl in which the substituents are selected from the group consisting of bromo, chloro, fluoro, iodo, C1-C5 alkyl, hydroxy, nitro, acetyl, alkoxy, carboxy, acetoxy, amino, mono- or di- alkyl amino, amido and acetamido; R1 and R2 independently are hydrogen or C1-C5 alkyl, n3, n4, n5, n6, n7, and n8 independently are zero or one; when n's are zeros, R3 and R4 together, R4 and R5 together, R5 and R6 together, and R7 and R8 together are double bonds ; when n's are ones, R3, R5, R6, R7 and R8 independently are hydrogen, R4 is hydrogen or methyl, or R3 and R4 together, R4 and R5 together, or R5 and R6 together are methylene.
描述了一种抑制 IgE 生成的方法,该方法包括以有效抑制 IgE 生成的量给药式......的前列腺素:
或其药学上可接受的无毒盐,其中 R 是氢、C1-C5 烷基、C3-C8 环烷基、苯基或单、二或三取代苯基,其中取代基选自溴、氯、氟、碘、C1-C5 烷基、羟基、硝基、乙酰基、烷氧基、羧基、乙酰氧基、氨基、单或二烷基氨基、氨基和乙酰氨基组成的组;R1 和 R2 独立地为氢或 C1-C5 烷基,n3、n4、n5、n6、n7 和 n8 独立地为 0 或 1;当 n 为 0 时,R3 和 R4 在一起、R4 和 R5 在一起、R5 和 R6 在一起、R7 和 R8 在一起为双键;当 n 为 1 时,R3、R5、R6、R7 和 R8 独立地为氢、R4 为氢或甲基、或 R3 和 R4 在一起、R4 和 R5 在一起、或 R5 和 R6 在一起为亚甲基。